Matthew W. Gilmour
Public Health Agency of Canada
72 Papers
560 Citations
Matthew W. Gilmour is an academic researcher from Public Health Agency of Canada. The author has contributed to research in topics: Biology & Streptococcus pneumoniae. The author has an hindex of 33, co-authored 72 publications. Previous affiliations of Matthew W. Gilmour include University of Winnipeg & Manitoba Health.
Chat about Author
Papers
Distinguishable epidemics of multidrug-resistant Salmonella typhimurium DT104 in different hosts
Alison E. Mather,Stuart Reid,Duncan J. Maskell,Julian Parkhill,Maria Fookes,Simon R. Harris,Derek J. Brown,J. E. Coia,Michael R. Mulvey,Matthew W. Gilmour,Liljana Petrovska,E. de Pinna,Makoto Kuroda,M. Akiba,Hidemasa Izumiya,Thomas R. Connor,Marc A. Suchard,Philippe Lemey,Dominic J. Mellor,Daniel T. Haydon,Nicholas R. Thomson +20 more
TL;DR: Contrary to current tenets supporting a single homogeneous epidemic, it is demonstrated that the bacterium and its resistance genes were largely maintained within animal and human populations separately and that there was limited transmission, in either direction.
Comparative genomics of Vibrio cholerae from Haiti, Asia, and Africa.
Aleisha Reimer,Gary Van Domselaar,Steven Stroika,Matthew G. Walker,Heather Kent,Cheryl L. Tarr,Deborah F. Talkington,Lori A. Rowe,Melissa Olsen-Rasmussen,Michael Frace,Scott Sammons,Georges Dahourou,Jacques Boncy,Anthony M. Smith,Philip Mabon,Aaron Petkau,Morag R. Graham,Matthew W. Gilmour,Peter Gerner-Smidt +18 more
TL;DR: A strain from Haiti shares genetic ancestry with those from Asia and Africa, and is thought to be the first of its kind in the world.
Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
George G. Zhanel,George G. Zhanel,Riley Love,Heather J. Adam,Heather J. Adam,Alyssa R Golden,Sheryl A. Zelenitsky,Frank Schweizer,Bala Kishan Gorityala,Philippe Lagacé-Wiens,Ethan Rubinstein,Ethan Rubinstein,Andrew Walkty,Andrew Walkty,Alfred S. Gin,Alfred S. Gin,Matthew W. Gilmour,Matthew W. Gilmour,Daryl J. Hoban,Daryl J. Hoban,Joseph P. Lynch,James A. Karlowsky +21 more
TL;DR: Data from the two completed Phase III clinical trials demonstrated that the studied tedizolid regimen had significantly less impact on hematologic parameters as well as significantly less gastrointestinal treatment-emergent adverse effects (TEAEs) than its comparator linezolid.
155
Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012
Walter Demczuk,Irene Martin,Averil Griffith,Brigitte Lefebvre,Allison McGeer,Marguerite Lovgren,Gregory J. Tyrrell,Shalini Desai,Lindsey Sherrard,Heather J. Adam,Heather J. Adam,Matthew W. Gilmour,Matthew W. Gilmour,George G. Zhanel +13 more
TL;DR: A baseline serotype distribution was established by age and region for 2058 invasive Streptococcus pneumoniae isolates collected during the implementation period of the 13-valent pneumococcal conjugate vaccine (PCV13) program in many parts of Canada in 2010.
121
Sequence typing confirms that a predominant Listeria monocytogenes clone caused human listeriosis cases and outbreaks in Canada from 1988 to 2010
Stephen J. Knabel,Aleisha Reimer,Bindhu Verghese,Mei Lok,Jennifer Ziegler,Jennifer Ziegler,Jeffrey M. Farber,Franco Pagotto,Morag R. Graham,Morag R. Graham,Celine Nadon,Celine Nadon,Celine Nadon,Matthew W. Gilmour,Matthew W. Gilmour,Matthew W. Gilmour +15 more
TL;DR: Human listeriosis outbreaks in Canada have been predominantly caused by serotype 1/2a isolates with highly similar pulsed-field gel electrophoresis patterns with congruent subtypes that substantiated a predominant clone that has been causing human illness across Canada for more than 2 decades.
116